Skip to content
Search AI Powered

Latest Stories

FTC & FDA Send Cease and Desists to Companies Selling Delta-8 Edibles Marketed as Common Children's Snacks 

FTC & FDA Send Cease and Desists to Companies Selling Delta-8 Edibles Marketed as Common Children's Snacks
FTC & FDA Send Cease and Desists to Companies Selling Delta-8 Edibles Marketed as Common Children's Snacks

The Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) have jointly taken action against several companies marketing edible products containing Delta-8 tetrahydrocannabinol (THC) in packaging that resembles popular snacks and candies commonly marketed to and consumed by children. The agencies have sent cease and desist letters to these companies, demanding immediate changes to their packaging practices. The move aims to protect children from mistaking THC-infused products for regular foods and inadvertently consuming them, posing potential health risks.

Addressing the Packaging Issue


Samuel Levine, Director of the FTC's Bureau of Consumer Protection, emphasizes that marketing THC products in packaging that can be easily mistaken by children is both reckless and illegal. The well-being of children must be safeguarded, and companies have a responsibility to ensure that their products are marketed safely and responsibly.

Dr. Janet Woodcock, Principal Deputy Commissioner of the FDA, points out that children are more vulnerable than adults to the effects of THC. Instances of children becoming sick or requiring hospitalization after consuming THC-infused "edibles" have been reported. The FDA warns against the sale of copycat food products containing Delta-8 THC (also referred to as Δ-8 THC), as they closely resemble popular foods that are appealing to children and can lead to unintended high-dose ingestion.

The Targeted Companies

The cease and desist letters were sent to the following companies:

The FTC has reviewed the online marketing of Delta-8 THC products sold by these companies and found that their advertising may violate Section 5 of the FTC Act, which prohibits unfair or deceptive acts in commerce. The letters emphasize the agencies' commitment to preventing practices that pose health or safety risks, especially to children, and highlight that imitating non-THC-containing food products misleads consumers.

Packaging Examples and Concerns

The Delta-8 THC products marketed by these companies, and likely dozens if not hundreds more nationwide, mimic a range of children's snacks and candies, further heightening the risk of confusion. 

For instance, Dr. Smoke, LLC sells THC-infused "Doritos" and "Cheetos" in packaging almost identical to popular snack brands, including the use of the same logos, designs, and mascots. 

The Haunted Vapor Room offers Delta-8 THC products named after and resembling Nerds Rope candy. 

Delta Munchies, LLC markets gummy products that resemble conventional gummy candies consumed by children.

The FTC demands that these companies immediately stop marketing edible Delta-8 THC products that imitate regular foods using packaging or advertising likely to appeal to young children requesting that each company provide a detailed account of the specific actions taken to address the concerns raised in the cease and desist letters within 15 days. Christine DeLorme, a staff attorney in the FTC's Bureau of Consumer Protection, is overseeing the matter.

Additionally, the FTC urges the companies to review all their marketing and product packaging for similar edible THC products, taking swift action to protect consumers, especially children.

Prior Joint FTC/FDA Actions

This recent joint effort by the FTC and FDA is not the first of its kind. In 2019, the agencies issued similar joint letters to sellers of cannabidiol (CBD) products, cautioning against advertising claims suggesting the prevention, treatment, or cure of human disease without reliable scientific evidence to support such claims.

In addition to the joint action taken by the Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA), it is important to understand what Delta-8 THC is, its derivation process, and why the FDA's move carries significance for the broader conversation around cannabis and legalization. 

What is Delta-8 THC

Delta-8 THC is a naturally occurring cannabinoid found in cannabis plants. It is a chemical compound similar to Delta-9 THC, the well-known psychoactive compound responsible for the intoxicating effects of marijuana. However, Delta-8 THC is known to have less potent psychoactive properties than Delta-9 THC, making it a popular choice for individuals seeking a milder cannabis experience and also for companies looking to profit from the lack of education and limited access to safe, legal cannabis. 

Is Delta-8 THC Safe

Delta-8 THC is derived from hemp, a variety of the cannabis plant that contains low levels of Delta-9 THC. 

The Farm Bill defined THC specifically as delta-9-THC, which is still illegal federally. With that definition, a market for delta-8 was born. 

Delta-8-THC is detectable only in trace amounts in both hemp and marijuana plants, but manufacturers have figured out a way to produce it from a third notable chemical in cannabis plants, CBD. CBD is present in large quantities in hemp plants, and because CBD is legal, they assert, so is delta-8.

The extraction process involves converting the precursor cannabinoid, cannabidiol (CBD), into Delta-8 THC through various methods such as isomerization or distillation. These processes aim to isolate and concentrate Delta-8 THC to achieve higher levels in the final product. 

The manufactured Delta-8-THC is typically added to gummies and vape cartridges and sold legally over the internet and in convenience stores and gas stations nationally. But because the products are unregulated, what’s on the label can differ from what’s inside the package, both in terms of the potency of delta-8 and other unanticipated ingredients, such as contaminants, heavy metals or mold, among other potentially harmful byproducts.

It’s unregulated, and because it’s synthetic, the way it’s made and who is selling it, there are plenty of opportunities for things to go wrong. 

Unfortunately for many of those operating in the legal cannabis industry, they are often lumped in with these bad actors, despite following very strict Federal, State and Municipal regulations and guidelines and putting customer safety first. 

The joint action by the FTC and FDA underscores the importance of responsible marketing practices, especially in the context of products that can potentially have significant health effects. The regulatory scrutiny serves as a reminder for companies to ensure that their products are marketed safely and responsibly, with a particular focus on protecting vulnerable populations. 

More For You

map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report byThe New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy

Selective Outrage Hurts NY Cannabis

Authored by: Veterans Holdings CEO Jason Ambrosino

Last week, the New York Medical Cannabis Industry Association (NYMCIA) issued a press release accusing licensed dispensaries of selling "out-of-state cannabis" and undermining the integrity of the legal market. Read the press release here.

Keep ReadingShow less
image of a circle of doctors and surgeons standing over and looking at a patient on operating room table
New Study Confirms Medical Cannabis Benefits in Cancer Care—Time for Policy to Catch Up
Photo by National Cancer Institute on Unsplash

Cannabis & Cancer: The Evidence Is In—So Why Is the Medical Establishment Still Dragging Its Feet?

If you've ever watched a loved one battle cancer—or been on that journey yourself—you already know the harsh truth: the pain is real, the nausea is relentless, the appetite is gone, and the side effects of treatment often feel worse than the disease. So when patients say cannabis helps, it shouldn’t take 10,000 studies for the medical community to take them seriously.

And yet, here we are.

Keep ReadingShow less
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Giphy

Aging & Cannabis: New Findings

For decades, cannabis has been widely regarded as a substance with potential cognitive risks, particularly when used over long periods. Governments across the globe have classified it as a controlled substance, citing concerns about the effects of marijuana use, including memory loss, diminished executive function, and long-term neurological impact. But new research is challenging this long-standing assumption, suggesting that cannabis use may not be linked to age-related cognitive decline—and might even be associated with better cognitive preservation over time.

A recent study published in PubMed (NIH, 2024) followed over 5,000 men for more than four decades to analyze the long-term cognitive effects of cannabis use. The results? Men with a history of cannabis use experienced less cognitive decline from early adulthood to late midlife compared to those who never used cannabis.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less